Jason Cavalier
CIK: 0001883290
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lyra Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Apr 1, 2026LYRA
Lyra Therapeutics, Inc.
Disposition(D)Direct667 shares- - Jan 6, 2026LYRA
Lyra Therapeutics, Inc.
Sale(S)Direct769 shares at avg. $3.36$3K - Jul 10, 2025LYRA
Lyra Therapeutics, Inc.
Sale(S)Direct684 shares at avg. $8.91$6K - Jan 8, 2025LYRA
Lyra Therapeutics, Inc.
Award(A)Direct420K shares- - Oct 16, 2024LYRA
Lyra Therapeutics, Inc.
Award(A)Direct100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 1, 2026 | LYRA Lyra Therapeutics, Inc. | Disposition(D) | 667 | - | $0 | Direct |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | Sale(S) | 769 | $3.36 | $2,587 | Direct |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | Sale(S) | 684 | $8.91 | $6,094 | Direct |
| Jan 8, 2025 | LYRA Lyra Therapeutics, Inc. | Award(A) | 420,000 | - | $0 | Direct |
| Oct 16, 2024 | LYRA Lyra Therapeutics, Inc. | Award(A) | 100,000 | - | $0 | Direct |
1-5 of 5 transactions
Jason Cavalier files insider reports with the SEC as Principal Financial Officer of Lyra Therapeutics, Inc. (LYRA). Signal8 holds 5 reported Form 4/5 transactions by Jason Cavalier since Sep 2024. The most recent reported transaction is a disposition to issuer (Form 4 code D) in LYRA, dated Apr 1, 2026.
About Cavalier Jason
Cavalier Jason (SEC CIK 0001883290) files insider reports with the SEC as Principal Financial Officer of Lyra Therapeutics, Inc. (LYRA).
Signal8 holds 5 ownership filings by Cavalier Jason, all Form 4s, filed between Oct 18, 2024 and Apr 3, 2026. Those filings report 5 transactions, from Oct 16, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cavalier Jason's filings is in WATERTOWN, MA.
Recent filings by Cavalier Jason
- Apr 1, 2026: Disposition to issuer transaction of LYRA shares (Form 4, code D).
- Jan 6, 2026: Open-market sale of LYRA shares (Form 4, code S).
- Jul 10, 2025: Open-market sale of LYRA shares (Form 4, code S).
- Jan 8, 2025: Grant or award of LYRA shares (Form 4, code A).
- Oct 16, 2024: Grant or award of LYRA shares (Form 4, code A).
Other insiders filing for Lyra Therapeutics, Inc. (LYRA)
- Smith W Bradford, Director
- Palasis Maria, Principal Executive Officer
- PERCEPTIVE ADVISORS LLC, 10% Owner
- MERRIFIELD C ANN, Director
- TOBIN JAMES R, Director
- snyderman nancy lynn MD, Director